PIM Kinase Inhibition Sensitizes Neuroblastoma to Doxorubicin
Author / Expert
Janet R. Julson, Colin H. Quinn, Nazia Nazam, Laura V. Bownes, Jerry E. Stewart, Elizabeth A. Beierle
Topic overview
Chemoresistance contributes to relapse in high-risk neuroblastoma. Cancer cells acquire resistance through multiple mechanisms, including drug efflux pumps. In neuroblastoma, multidrug resistance-associated protein-1 (MRP1/ABCC1) efflux pump expression correlates with worse outcomes. These pumps are regulated by PIM kinases, a family of serine–threonine kinases, overexpressed in neuroblastoma. We hypothesized PIM kinase inhibition would sensitize neuroblastoma cells by modulating MRP1.
Comments